Current Quandaries in Cancer-Associated Anemia

Restricted access

Dr. Jeffrey A. Gilreath is Clinical Assistant Professor of pharmacy at the University of Utah College of Pharmacy in Salt Lake City, Utah. He is Vice-Chair of the NCCN Guidelines Panel for Cancer- and Chemotherapy-Induced Anemia.The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.Dr. George M. Rodgers is Professor of Medicine and Pathology at the University of Utah Health Sciences Center in Salt Lake City, Utah. He is Chair of the NCCN Guidelines Panel for Cancer- and Chemotherapy-Induced Anemia.
  • 1.

    RodgersGMIIIBeckerPSBlinderM. Cancer-and chemotherapy-induced anemia. J Natl Compr Canc Netw2012;10:628653.

  • 2.

    ToniaTMettlerARobertN. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev2012;12:CD003407.

  • 3.

    KhoranaAAFrancisCWBlumberg. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med2008;168:23772381.

    • Search Google Scholar
    • Export Citation
  • 4.

    WangTLuoLHuangH. Perioperative blood transfusion is associated with worse clinical outcomes in resected lung cancer. Ann Thorac Surg2014;97:18271837.

    • Search Google Scholar
    • Export Citation
  • 5.

    BarniSCabidduMGuarneriP. The risk for anemia with targeted therapies for solid tumors. Oncologist2012;17:715724.

  • 6.

    GilreathJAStenehjemDDRodgersGM. Diagnosis and treatment of cancer-related anemia. Am J Hematol2014;89:203212.

  • 7.

    PfeifferCMJohnsonCLJainRB. Trends in blood folate and vitamin B-12 concentrations in the United States, 1988-2004. Am J Clin Nutr2007;86:718727.

    • Search Google Scholar
    • Export Citation
  • 8.

    HedenusMBirgegårdGNäsmanP. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia2007;21:627632.

    • Search Google Scholar
    • Export Citation
  • 9.

    AuerbachMBallardHTroutJR. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol2004;22:13011307.

    • Search Google Scholar
    • Export Citation
  • 10.

    ShuTJingCLvZ. Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis [published online ahead of print June 21, 2014]. Eur J Haematoldoi: 10.1111/ejh.12402.

    • Search Google Scholar
    • Export Citation
  • 11.

    CookeKSHinkleBSalimi-MoosaviH. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood2013;122:30543061.

    • Search Google Scholar
    • Export Citation
  • 12.

    SedighiOMakhloughAJanbabaiGNeemiM. Comparative study of intravenous iron versus intravenous ascorbic acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial. Nephrourol Mon2013;5:913917.

    • Search Google Scholar
    • Export Citation
  • 13.

    AttallahNOsman-MalikYFrinakSBesarabA. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis2006;47:644654.

    • Search Google Scholar
    • Export Citation
  • 14.

    BacchettaJZaritskyJJSeaJL. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol2014;25:564572.

  • 15.

    SunCCVajaVBabittJLLinHY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol2012;87:392400.

    • Search Google Scholar
    • Export Citation
  • 16.

    ChandelNSTuvesonDA. The promise and perils of antioxidants for cancer patients. N Engl J Med2014;371:177178.

  • 17.

    JelkmannW. The ESA scenario gets complex: from biosimilar epoetins to activin traps. Nephrol Dial Transplantin press.

  • 18.

    WeiseMBielskyMCDe SmetK. Biosimilars: what clinicians should know. Blood2012;120:51115117.

  • 19.

    WallerCF. Biosimilars and their use in hematology and oncology. Commun Oncol2012;9:198205.

  • 20.

    Affymax and Takeda announce a nationwide voluntary recall of all lots of OMONTYS (peginesatide) injection. Available at: http://www.fda.gov/safety/recalls/ucm340893.htm. Accessed July 7 2014.

    • Search Google Scholar
    • Export Citation
  • 21.

    BernhardtWMWiesnerMSScigallaP. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol2010;21:21512156.

    • Search Google Scholar
    • Export Citation
  • 22.

    ZhuHWangDZhangL. Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia [published online ahead of print July 2, 2014]. Oncol Repdoi: 10.3892/or.2014.3298.

    • Search Google Scholar
    • Export Citation
  • 23.

    WangJNiZDuanZ. Altered expression of hypoxia-inducible factor-1α (HIF-1α) and its regulatory genes in gastric cancer tissues. PLoS One2014;9:e99835.

    • Search Google Scholar
    • Export Citation
  • 24.

    ManciniMGariboldiMBTaianaE. Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells. Br J Cancer2014;110:28652873.

    • Search Google Scholar
    • Export Citation
  • 25.

    TortiSVTortiFM. Iron and cancer: more ore to be mined. Nat Rev Cancer2013;13:342355.

  • 26.

    RatcliffePJ. Oxygen sensing and hypoxia signaling pathways in animals: the implications of physiology for cancer. J Physiol2013;591:20272042.

    • Search Google Scholar
    • Export Citation
  • 27.

    PaulsonRF. Targeting a new regulator of erythropoiesis to alleviate anemia. Nat Med2014;20:334335.

  • 28.

    CarsonJLGrossmanBJKleinmanS. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med2012;157:4958.

  • 29.

    ESA APPRISE oncology program. Available at: https://www.esa-apprise.com/ESAAppriseUI/ESAAppriseUI/default.jsp. Accessed July 11 2014.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 68 68 4
PDF Downloads 8 8 0
EPUB Downloads 0 0 0